President and CEO, Cogent Biosciences
Chuck leads the company. Before founding Cogent Biosciences, Chuck led partnering for Novartis research, and was responsible for all efforts in drug discovery up through Phase II clinical development. He brings deal experience in biotech and academic collaborations, product in-licensing, spin-outs, and strategic equity investing in early stage companies. Prior to Novartis, Chuck held both scientific and business management roles in biotechnology. Chuck received his PhD from the University of California, San Francisco, and completed his post-doctoral training at Harvard University / Massachusetts General Hospital. In addition to his responsibilities at Cogent, Chuck serves as a director on the board of Gigagen, Inc. and as vice chair of the Massachusetts Biotechnology Council (‘MassBIO’). Chuck keeps occupied flying helicopters, building robots, and playing with chainsaws.